Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, Dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00718718 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT00718718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00718718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, Dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Lead sponsor
Centocor, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 11, 2008
Completion date
March 3, 2011
Enrollment
187 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid